(Press-News.org) ATS 2014, SAN DIEGO ─ Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers.
The study was presented at the 2014 American Thoracic Society International Conference.
UCSD pioneered PTE in the 1970s for patients who suffered from chronic thromboembolic pulmonary hypertension (CTEPH). During PTE, surgeons put a patient on a heart-lung machine, cool the body to reduce its need for oxygen and then turn the machine off for up to 20 minutes so they can remove clots and scar tissue from the patient's arteries. Because of the procedure's complexity, it has been used, until recently, only to help patients whose pulmonary thromboembolic disease causes severe hypertension and has not responded to other therapies.
"Over the past five years, an increasing number of patients with symptomatic chronic thromboembolic disease, without severe pulmonary hypertension, are being offered and choosing to undergo the surgery, said lead investigator Daniel Crouch, MD, a third-year pulmonary and critical care fellow at UCSD. "These patients have symptoms that create a major burden in their lives. However, given that they do not have severe pulmonary hypertension and cardiac dysfunction, the benefits of the surgery must greatly outweigh the risks. "
In a retrospective chart review of patients who underwent PTE at UCSD between July 2010 and June 2013, Crouch found that 64 subjects had pre-operative pulmonary resistance values (PVRs) less than 300 dyn∙/cm5 and 355 patients had PVRs above 300dyn∙/cm5. (The value is used at UCSD as a guide to identify patients with severe and non-severe pulmonary hypertension.) In the UCSD study, both groups had similar mean age and gender composition, while the body mass index (32.57 vs 30.18) was higher in the low PVR group.
Crouch and his colleagues found that those in the low PVR group had lower mortality (0 vs. 1.1%) and fewer complications, including delirium (7.8% vs. 14.9%), pneumonia/tracheobronchitis (6.3% vs. 15.5%), and a statistically significant lower rate of reperfusion lung injury (7.8% vs. 25.9%), The low PVR group also experienced statistically significant recoveries, with less time spent on the ventilator (1.7 vs. 3.2 days), in the ICU (4 vs. 5.8 days) and in the hospital (13 vs. 16.3 days).
Anecdotally, Crouch added, patients in the low PVR group showed "great benefit" in follow up visits. Nonetheless, the program is conducting a follow-up study to evaluate formally improvement in their functional status and quality of life. With higher (BMI) and a higher rate of simultaneous coronary artery bypass grafting (9.4% vs. 15.5%), he said, those in the low group may have other factors that contribute to their symptoms before surgery.
"Although pulmonary thromboendarterectomy is the procedure of choice for CTEPH, there are important questions to answer before it can be considered the treatment of choice in the low PVR patient population," Crouch said. "As with anything we offer patients, we want to prove it's the best therapy."
INFORMATION:
* Please note that numbers in this release may differ slightly from those in the abstract. Many of these investigations are ongoing; the release represents the most up-to-date data available at press time.
Abstract 54362
Pulmonary Thromboendarterectomy In Patients With Chronic Pulmonary Thromboembolic Disease And Low Preoperative Pulmonary Vascular Resistance
Type: Scientific Abstract
Category: 18.08 - Pulmonary Embolism: Acute and Chronic (PC)
Authors: D.R. Crouch, P.F. Fedullo, W.R. Auger; UC San Diego - San Diego, CA/US
Abstract Body
Rationale: Chronic thromboembolic pulmonary hypertension (CTEPH) is potentially reversible with pulmonary thromboendarterectomy (PTE). Classically, this surgery has been reserved for patients with significantly elevated pulmonary pressures. More recently, a growing number of patients are being diagnosed with symptomatic chronic pulmonary thromboembolic disease without evidence of severe pulmonary hypertension. We reviewed our experience with patients with PVRs less than 300 compared to the patients with higher pre-operative PVRs at UCSD.
Methods: This was a retrospective chart review of patients with chronic pulmonary thromboembolic disease who underwent PTE surgery between July, 2010 through June, 2013. The low PVR group includes 64 subjects with a PVR less than or equal to 300 dyn•s/cm5 (mean PVR 209) and the high PVR group includes 355 subjects with pre-operative PVR above 300 dyn•s/cm5 (mean PVR 756). Patient demographics, pre-operative and post-operative hemodynamics, hospital and ICU length of stay, ventilator days, complication rates, associated procedures performed, and mortality were reviewed.
Results: Both groups had a similar mean age, gender composition, and BMI. The low PVR group spent less time on the ventilator (1.7 vs. 3.2 days), less time in the ICU (4 vs. 5.8 days), and less time in the hospital (13 vs. 16.3 days) compared to the high PVR group. There were fewer overall complications in the low PVR group, most notably lower rates of reperfusion lung injury (7.8% vs. 25.9%), delirium (7.8% vs. 14.9%), and pneumonia/tracheobronchitis (6.3% vs. 15.5%). There was a high rate of postoperative pericardial effusion in the low PVR group (10.9% vs. 5.1%). Low PVR patients had a higher rate of simultaneous CABG (9.4% vs. 7.0%) and a lower rate of PFO closure at the time of surgery (12.5% vs. 22%). Mortality was 0% in the low PVR group and 1.1% in the high PVR group.
Conclusions: For patients with symptomatic chronic thromboembolic disease and a PVR less than 300, surgical intervention carries a lower mortality risk, fewer complications, and faster recovery with shorter ICU and hospital stays as compared to those patients with PVRs over 300. These data suggest that surgical intervention is a reasonable and relatively safe therapeutic option in this patient population. Further studies are currently ongoing to evaluate this group for clinical improvements in functional status and quality of life after surgery.
Patients with low pulmonary vascular resistance may benefit from complex procedure for PH
2014-05-18
ELSE PRESS RELEASES FROM THIS DATE:
Urine test could help clinicians spot blood clots in at-risk patients
2014-05-18
ATS 2014, SAN DIEGO ─ A new study by researchers from California and Canada indicates a simple urine test can indicate the presence of venous thromboembolism, a blood clot that has broken free from its point of origin and which travels through the bloodstream, eventually lodging in a vein. The test evaluates the levels of fibrinopeptide B (FPB), a small peptide that's released when a thrombosis forms and which is removed from the body through urine.
The results of the study will be presented at the American Thoracic Society's 2014 International Conference here.
Study ...
Sleep apnea is common after acute respiratory failure
2014-05-18
ATS 2014, SAN DIEGO ─ Clinically important sleep apnea is common among survivors of acute respiratory failure, according to a new study presented at the 2014 American Thoracic Society International Conference.
"Insomnia is a frequent complaint among survivors of critical illness," said Dr. Elizabeth Parsons, MD, MSc, of the Division of Pulmonary & Critical Care Medicine at the University of Washington in Seattle. "We examined a small cohort of survivors of acute respiratory failure to understand modifiable contributors to insomnia, including sleep apnea."
The ...
Bacteria in mouth may diagnose pancreatic cancer
2014-05-18
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases, according to research presented today at the annual meeting of the American Society for Microbiology. These findings could form the basis for a test to diagnose the disease in its early stages.
"Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer," says Pedro Torres of San Diego State University who presented ...
Temple-led study finds no benefit in taking statin drugs for COPD exacerbation prevention
2014-05-18
(Philadelphia, PA) – A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.
Dr. Criner, who served as the study's Principal Investigator, will report the results on May 18 at the American Thoracic Society's annual international scientific meeting in San ...
QVAR® real-world study to be presented at annual ATS International Conference
2014-05-18
Jerusalem, May 18, 2014 – Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR® will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014. QVAR® is an inhaled corticosteroid (ICS) indicated in the maintenance treatment of asthma as a prophylactic therapy in patients 5 years of age and older.
Data to be presented at the meeting evaluated the benefit of treating asthma with small particle treatments, like QVAR®, in comparison ...
Study debunks common myth that urine is sterile
2014-05-18
Bacteria live in the bladders of healthy women, discrediting the common belief that normal urine is sterile. This finding was presented today by researchers from Loyola University Chicago at the 114th General Meeting of the American Society for Microbiology in Boston.
"Doctors have been trained to believe that urine is germ-free," said Linda Brubaker, MD, MS, co-investigator and dean, Loyola University Chicago Stritch School of Medicine (SSOM). "These findings challenge this notion, so this research opens the door to exciting new possibilities for patient treatment." ...
Gum disease bacteria may cause heart disease
2014-05-18
A University of Florida study shows that the same bacteria that cause gum disease also promotes heart disease – a discovery that could change the way heart disease is diagnosed and treated. Researchers report their findings today at the annual meeting of the American Society for Microbiology.
"We report evidence that introduction of oral bacteria into the bloodstream in mice increased risk factors for atherosclerotic heart disease. Our hope is that the American Heart Association will acknowledge causal links between oral disease and increased heart disease. That will ...
Painkillers may decrease susceptibility to recurring urinary infections
2014-05-18
Women plagued by repeated urinary tract infections may be able to prevent the infections with help from over-the-counter painkillers, according to research presented at the annual meeting of the American Society for Microbiology.
Scientists at Washington University School of Medicine in St. Louis found that inhibiting COX-2, an immune protein that causes inflammation, eliminated recurrent urinary tract infections in mice. COX-2 is one of the proteins blocked by non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.
"If we can confirm this link in clinical ...
Bacteria in urine could contribute to overactive bladder
2014-05-18
Contrary to popular belief, urine is not sterile and the bacteria in it may be associated with overactive bladder (OAB) in some women, according to research presented today at the annual meeting of the American Society for Microbiology.
"The presence of certain bacteria in women with overactive bladder appear associated with OAB symptoms," said Evann Hilt, lead investigator and second-year master's student at Loyola University Chicago.
For years doctors have been trained to believe that urine is germ-free. In 2012, Hilt's coauthors used modern, DNA-based detection ...
Heart failure hospitalization more than doubles in IBD flares
2014-05-18
Athens, 18 May 2014: Heart failure hospitalisation more than doubles during inflammatory bowel disease (IBD) flares, according to a study of more than 5 million Danish people. The research was presented today at the Heart Failure Congress 2014, held 17-20 May, in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.
Dr Søren L. Kristensen, lead author, said: "Previous studies have shown an association between chronic inflammatory diseases (psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ...